Sorry, you need to enable JavaScript to visit this website.

Skip to main content


The R&D Leadership Team

Our Research & Development Leadership Team


We share an overarching mission: to discover and develop innovative medicines and solutions that transform individuals’ lives and solve the most important unmet medical needs of our time. As Janssen R&D, we work together to harness our combined knowledge and resources, leverage the power and promise of outstanding science and enhance the length and quality of life for people throughout the world.

Research & Development

Research & Development

Judith Hinton Andrew, Rock Composite 22
Judith Hinton Andrew, Rock Composite 22



William N. Hait, M.D., Ph.D. is Global Head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson. In this role, he leads the global Research & Development (R&D) group in its mission to discover and develop innovative new medicines to address the world’s most serious unmet medical needs.

Bill joined the Johnson & Johnson Family of Companies in 2007 and assumed the role of Global Therapeutic Area Head, Oncology, in 2009.

Before that he was the founding Director of The (Rutgers) Cancer Institute of New Jersey, which he led to receive the National Cancer Institute’s highest designation of Comprehensive Cancer Center in 2002. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.

After earning his B.A. from the University of Pennsylvania in Philadelphia, Bill received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania in Philadelphia, where he was elected to Alpha Omega Alpha. He joined the faculty of Yale University School of Medicine in New Haven, Connecticut in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

Bill devoted his time to numerous advisory and editorial boards. He was Editor-in-Chief of Clinical Cancer Research and Associate Editor of Cancer Research, served as President of the American Association for Cancer Research from 2007–2008 and currently serves as Treasurer. He sits on various committees for the American Association of Cancer Research (Chair, Clinical Cancer Research Committee), the American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors), the National Cancer Institute Board of Scientific Advisors and is Chairman of the Executive Management Committee of Stand Up to Cancer. He currently is a member of the Rutgers Cancer Institute of New Jersey Director's Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, the Stand Up to Cancer Scientific Advisory Board, The Board of Directors of Research! America and the Vanderbilt University Biomedical Science Advisory Board.

Bill has received numerous awards and honors including the Burroughs Wellcome Award in Clinical Pharmacology, election to the American Society of Clinical Investigation, and in 2013 he was elected as a Fellow of the AACR Academy.

William N. Hait, M.D., Ph.D.

Global Head, Research & Development



Dr. Mathai Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.

Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.

Prior to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products, two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his medical degree. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University's Department of Chemistry, working with George Whitesides. He received his Bachelors of Science in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

Mathai Mammen, M.D., Ph.D.

Global Head, Science and Development

As leader of the global Janssen R&D Operations team, Stef Heylen, M.D. oversees operational excellence and execution of the company’s clinical development programs.

In his previous role, Stef served with the Johnson & Johnson Innovation Program Office supporting the Johnson & Johnson Chief Scientific Officer in driving meaningful innovation and leveraging innovation capabilities across all sectors of the enterprise. He also was Head of R&D and Chief Medical Officer for Janssen Alzheimer Immunotherapy R&D, LLC, and he developed and implemented an integrated Research and Early Development (RED) Neuroscience strategy for the Beerse, Belgium site as Chief Medical Officer, Johnson & Johnson Pharmaceutical R&D, RED EU. From 2003 to 2007, Stef served as Site Head, Vice President of Development and Chairman of the Development Management Committee for Tibotec. During his tenure, two of the company’s HIV medicines were granted accelerated approval.

Before joining Tibotec, Stef was Vice President, Development & Regulatory Affairs at Crucell in Leiden, the Netherlands, and held several senior positions within Janssen including Vice President, Global Regulatory Affairs and Pharmacovigilance, and Vice President, Medical Affairs for the Europe, Middle East and Asia (EMEA) region. He joined the Janssen Research Foundation in 1987 and led the global clinical development of one of the most successful Janssen antipsychotic medicines.

Stef obtained his M.D. at the University of Leuven, Belgium, and the Prince Leopold Institute for Tropical Medicine in Antwerp, Belgium. He is a 1993 recipient of the Dr. Paul Janssen Award for R&D.

Stef Heylen, M.D.

Chief Operating Officer, Janssen Research & Development

Lawrence Blatt, Ph.D. is responsible for co-leading the Infectious Diseases & Vaccines (IDV) Therapeutic Area at Janssen Research & Development. Prior to joining the Johnson & Johnson Family of Companies, Lawrence founded and was President and Chief Executive Officer of Alios BioPharma, Inc., the clinical stage biopharmaceutical company focused on developing therapies for viral diseases that was acquired by Johnson & Johnson in 2014. He was named as key inventor on several Alios patents and won the 2012 Ernst & Young Entrepreneur of the Year Award for Life Sciences.

Lawrence spent 30 years in pharmaceutical R&D with a specific focus on the biology of the immune system, antiviral therapies and relevant therapeutic interventions. Before forming Alios, he was Chief Scientific Officer of InterMune, Inc. where he led the discovery and development of an HCV protease inhibitor partnered with Roche. From 1998 to 2002, Lawrence was Vice President of Research at SIRNA. From 1996 to 1998, he served as Vice President, Product Development at National Genetics Institute where he pioneered the use of molecular diagnostics to drive therapeutic treatment decisions for viral infections. He began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for a consensus interferon product leading to approval by the United States Food and Drug Administration (FDA).

Lawrence earned his B.S. in Microbiology from Indiana University, a Master's in Business Administration at the California State University, Northridge, and a Doctorate in Public Health Administration at the University of La Verne, California.

Lawrence Blatt, Ph.D., M.B.A.

Global Therapeutic Area Head, Infectious Diseases & Vaccines

As Global Head, Discovery Sciences at Janssen Research & Development, Dash Dhanak, Ph.D. leads an organization responsible for supporting and enabling the discovery and early development of novel small molecule therapeutics.

Prior to joining Janssen, Dash spent 25 years at GlaxoSmithKline (GSK), most recently as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit. Dash received a B.S. in Chemistry from the University Of Manchester Institute of Science and Technology and a Ph.D. from the University of London, both in the United Kingdom. He subsequently carried out postdoctoral research in natural product synthesis at Northwestern University in Illinois, United States prior to joining GSK. In addition, he has published extensively on a variety of drug discovery topics.

Dash is a member of the American Association of Cancer Research Epigenome Task Force, has participated in the American Chemical Society Pharma Leaders Forum, as well as the American Cancer Society Peer Review Committee on Cancer Drug Development and the Multiple Myeloma Research Foundation Peer Review Committee. In addition, he has been an invited speaker at major scientific conferences.

Dash Dhanak , Ph.D.

Global Head, Discovery Sciences

Susan B. Dillon, Ph.D. has end-to-end responsibility for Immunology small and large molecule research, drug discovery, biomarkers, translational medicine, clinical development and life cycle management. She leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for patients with serious autoimmune, inflammatory and respiratory diseases.

Sue joined the Johnson & Johnson Family of Companies through the Centocor R&D Discovery Research Group in 2001 and has held positions of increasing responsibility leading to her 2007 appointment as Senior Vice President, Research, and Head of Early Development, Biologics. Under her leadership, the Centocor R&D discovery organization produced a strong pipeline of novel biologic new molecular entities (NMEs) and built world-class capabilities in protein drug discovery through a combination of internal efforts, acquisitions and partnerships.

An experienced leader in large and small molecule drug discovery, Sue has held senior positions at several pharmaceutical companies, including SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Kosan Biosciences (acquired by Bristol Myers Squibb).

Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, in Philadelphia, Pennsylvania. She completed a National Institutes of Health (NIH)-sponsored postdoctoral fellowship in Immunology at Duke University in Durham, North Carolina, has published more than 50 scientific articles and is inventor on three issued patents. In 2007, Susan was awarded the Distinguished Alumni Award from Thomas Jefferson University, and in 2013 she was selected by FierceBiotech as one of the “Top Women in Biotech.”

Susan B. Dillon, Ph.D.

Global Therapeutic Area Head, Immunology

As Global Therapeutic Area Head of Oncology, Peter Lebowitz, M.D., Ph.D. has end-to-end responsibility for Oncology Research & Development, from discovery through development and life cycle management. He leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for oncologic and hematologic diseases with high unmet medical need.

Prior to taking on the Therapeutic Area Head role, Peter was Head of the Hematologic Malignancy Disease Area. In this role, he was responsible for strategic oversight and execution of the Janssen hematologic malignancy drug discovery and development programs. Before joining Janssen, Peter was Vice President in both early and late-stage clinical development for another leading pharmaceutical company, where he successfully filed 10 Investigational New Drug (IND) applications with the United States Federal Drug Administration (FDA), played a major role in the global registration of three oncology drugs and led major projects from preclinical discovery through pivotal Phase 3 trials.

Prior to joining the industry, Peter was Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center in Washington, D.C., where he established an independently funded translational and clinical research program and was a Principal Investigator on numerous clinical research trials. Peter graduated from Harvard University in Cambridge, Massachusetts and earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. He then completed his hematology/oncology fellowship at the National Cancer Institute, National Institutes of Health.

Peter Lebowitz, M.D., Ph.D.

Global Therapeutic Area Head, Oncology

James F. List, M.D., Ph.D. is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for improving cardiovascular and diabetes care and disease interception. Jim has end-to-end research and development responsibility for the Janssen CVM portfolio, including drug discovery, clinical development, and external innovation. Jim joined Janssen in 2014.

Prior to joining Janssen, James served with Bristol-Myers Squibb as Vice President, Diabetes Development with responsibility for the diabetes joint venture alliance with AstraZeneca.

Earlier in his career, James was a faculty member of the Harvard Medical School in Cambridge, Massachusetts with clinical responsibilities in General Endocrinology and Thyroid. He graduated from Stanford University in Stanford, California and completed his M.D. and Ph.D. from the University of Minnesota in Minneapolis, Minnesota. He completed his medical training at Brigham and Women’s Hospital, Boston Children’s Hospital and the Massachusetts General Hospital, and is board certified in Internal Medicine, Pediatrics and Endocrinology.

James List, M.D., Ph.D.

Global Therapeutic Area Head, Cardiovascular & Metabolism

The Neuroscience Therapeutic Area is headed by Husseini Manji, M.D., F.R.C.P.C. Husseini was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, National Institutes of Health (NIH), and Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor at Duke University in Durham, North Carolina. Husseini received his B.S. (Biochemistry) and M.D. from the University of British Columbia in Vancouver. Following residency training, he completed fellowship training at the National Institute of Mental Health (NIMH) and obtained extensive additional training in cellular and molecular biology at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The major focus of Husseini’s research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics.

Husseini is the recipient of numerous research and clinical awards, including the NIMH Director’s Career Award for Significant Scientific Achievement, the A.E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the National Alliance for Research on Schizophrenia and Depression (NARS AD) Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the Joel Elkes Award for distinguished research from the American College of Neuropsychopharmacology (ACNP), the Canadian Association of Professors Award, the Brown University School of Medicine Distinguished Researcher Award, the Depression and Bipolar Support Alliance (DBSA) Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction and the NIMH award for excellence in clinical care and research.

In addition to his neuroscience research and biomarker and therapeutics development endeavors, Husseini has also been actively involved in medical and neuroscience education undertakings, and has served as a member of the National Board of Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee and numerous national curriculum committees.

He founded and co-directed the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Neuropsychiatric Illness and received both the NIMH Mentor of the year and NIMH Supervisor of the year awards and the Henry and Page Laughlin Distinguished Teacher Award.

Husseini has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. He was editor of Neuropsychopharmacology Reviews: The Next Generation of Progress, deputy editor of Biological Psychiatry, associate editor of the journal Bipolar Disorders and has been a member of the editorial board of numerous journals. He was inducted into the National Academy of Sciences’ Institute of Medicine (IOM), has been a Councilor of both the ACNP and Society of Biological Psychiatry, co-chairs the NIH Biomarkers Neuroscience Steering Committee, chaired the ACNP’s Task Force on New Medication Development, is a scientific advisor to the One Mind campaign (a public-private partnership that seeks to develop the United States’ first 10-year plan for research in neuroscience), has been named to the board of the International Neuroethics Society and is recent past president of the Society of Biological Psychiatry.

Husseini K. Manji, M.D., F.R.C.P.C.

Global Therapeutic Area Head, Neuroscience

Dr. Jay Siegel is Chief Biotechnology Officer and Head of Scientific Strategy and Policy, Johnson & Johnson. In these roles, he is actively engaged in research and development (R&D) leadership, and in policy development at the national and international levels with regard to scientific and regulatory issues.

Dr. Siegel joined Johnson & Johnson in 2003 as President of Centocor Research & Development, Inc., and subsequently served as Group President of R&D with oversight of research and development in Biotechnology, Immunology and Oncology. Dr. Siegel later served as Head of Global Regulatory Affairs for Janssen, the pharmaceutical companies of Johnson & Johnson, and also led Janssen’s Biotechnology Center of Excellence.

Before joining Johnson & Johnson, Dr. Siegel spent 20 years at the United States Food and Drug Administration (FDA) Center for Biologics Evaluation & Research in positions of increasing responsibility regulating the biotechnology industry.

Dr. Siegel received a Bachelor of Science in Biology from the California Institute of Technology and an medical degree from Stanford University. He trained in Internal Medicine at the University of California, San Francisco, and in Infectious Diseases and Immunology at Stanford University.

Dr. Siegel is recipient of numerous honors including the United States Public Health Service’s highest honor, the Distinguished Service Medal and, twice, the U.S. Health & Human Services Secretary’s Award for Distinguished Service. He has been elected to fellowship in the American College of Physicians and the Society for Clinical Trials and has authored numerous publications in the areas of clinical trial design, biotechnology, immunology, and drug development policy. He currently serves on the Executive Committees and the Boards of Directors of the Biotechnology Industry Organization (BIO) and the Alliance for Regenerative Medicine.


Chief Biotechnology Officer and Head of Scientific Strategy and Policy Johnson & Johnson

Sanjaya Singh, Ph.D., is Global Head, Janssen BioTherapeutics within Janssen Research & Development. Sanjaya is responsible for leading an organization focused on biotherapeutic research, discovery, toxicology, clinical pharmacology and strategic external collaboration. In this role, Sanjaya drives the strategy and overall vision to expand and apply the capabilities of Janssen Research & Development to the discovery and development of protein, peptide and cell-based therapeutics.

Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. Prior to joining Johnson & Johnson, Sanjaya spent nine years at Boehringer Ingelheim, most recently serving as Vice President, Biotherapeutics Discovery. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.

In the realm of academia, Sanjaya held a faculty position in the Department of Molecular Biology at the Institute of Life Sciences in India. An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents.

Sanjaya earned a Ph.D. in Molecular Biology from Banaras Hindu University, Varanasi, Uttar Pradesh, India. He served as a Postdoctoral Fellow in the Department of Molecular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, and as a Research Associate in the Department of Biochemistry and Molecular Biology, also at MD Anderson Cancer Center in Texas.


Global Head, Janssen BioTherapeutics

As head of the Global Regulatory Affairs (GRA) within Janssen Pharma, Karin Van Baelen leads an organization of approximately 900 highly qualified colleagues who foster relationships with Health Authorities around the world and deliver innovative healthcare solutions to patients. Under her leadership, the GRA organization influences and interprets global regulatory requirements and enables our company to meet those guidelines. In addition, GRA oversees the development of regulatory strategy for products from all therapeutic areas, as well as the delivery of high-quality, on-time regulatory submissions and approvals. GRA also engages in policy development at national and international levels in the regulatory, biotechnology and clinical development arenas

Previously, Karin served as Vice President of Regional Regulatory Affairs and Global Regulatory Operations, leading activities in Europe, Middle East, Africa, Russia (EMEA), Asia Pacific and Latin America and overseeing the Labeling & Submissions Management organization.  From 2008 to 2013, she led the EMEA Regional Regulatory Affairs team in all regulatory aspects for all therapeutic areas and all operating company regulatory organizations in the region. Karin also served as Vice President of Global Regulatory Affairs for Tibotec BVBA where she created and led its global regulatory team and contributed to the development and approvals of several products in the Janssen Infectious Diseases & Vaccines portfolio. She also worked with GRA at the Janssen Research Foundation and was responsible for the worldwide registrations of several key products, including medications for severe mood disorders and pain. Karin joined Johnson & Johnson in 1993 from Upjohn Benelux where she submitted numerous Marketing Authorization Applications and obtained approvals in Europe and emerging markets.

Karin has a strong record of developing successful leaders and served as the EMEA Diversity & Inclusion regional champion.

Karin obtained her Doctor of Pharmacy (Pharm.D.) degree at the University of Antwerp, Belgium in 1988. Karin serves with the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) Scientific Regulatory & Manufacturing Policy Committee (SRMPC) and with the Pharmaceutical Research and Manufacturers of America’s Regulatory Affairs Coordination Committee (RACC). 

Karin Van Baelen, Pharm. D.

Head, Global Regulatory Affairs

Johan Van Hoof, M.D. received his medical degree (cum laude) from the University of Antwerp, Belgium, and was a research fellow in the Department of Anatomy and Embryology at Rijksuniversitair Centrum Antwerpen, Belgium. He studied business management at Krauthammer International School and the International Executive Programme INSEAD, Fontainebleau, France.

Johan joined the Johnson & Johnson Family of Companies in April 2005 as Vice President, Data Management and Early Clinical Development. Following roles as Chief Operating Officer (COO) of Johnson & Johnson Pharmaceutical Research, LLC, and Head of the Global Development Organization, he was appointed Global Therapeutic Area Head for Infectious Diseases and Vaccines in 2010. Since 2011, in addition, he has been overseeing R&D at Crucell, the specialized vaccine company acquired, as their Chief Operating Officer and Managing Director.

Before joining the Johnson & Johnson Family of Companies, Johan acquired more than 20 years’ experience in the vaccine industry, having worked with Pasteur Mérieux Connaught, Chiron Vaccines and GlaxoSmithKline (GSK) Biologicals. During this period, he held leadership roles with increasing responsibilities, including Head New Product Development at GSK Biologicals. He was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis (pediatric combined vaccines), meningitis, rotaviral diarrhea, hepatitis, flu and HPV.

Johan Van Hoof, M.D.

Global Therapeutic Area Head, Infectious Diseases and Vaccines

Werner Verbiest is Global Head of Janssen Diagnostics, which was formed from the legacy organizations Virco (Infectious Diseases), Veridex (Oncology) and the Johnson & Johnson Companion Diagnostics Center of Excellence. Janssen Diagnostics focuses on personalized medicine within Janssen, incorporating therapeutic, diagnostic and real world data/health information technology solutions to improve patient outcomes.

Werner joined the Johnson & Johnson Family of Companies in 2002 following the acquisition of Tibotec-Virco. Before joining, he was active since 1992 in HIV drug development and hepatitis B therapeutic vaccine development in the International Clinical Research & Development group of the Janssen Research Foundation.  He was one of the first employees of Virco in 1997 and had an instrumental role in Virco’s growth as Project and Business Development Director (1998), Managing Director (Virco Ireland, Ltd, 1999), Vice President of New Products Marketing and Pharma Business (2001) and General Manager from 2004 until its integration into Janssen Diagnostics.

Werner has been continually active in all phases of HIV clinical trial strategy and implementation, biomarker development (collaborative surrogate marker validation working groups with the United States Food andl Drug Administration and the European Medicines Agency), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach both within and outside of Johnson & Johnson, including several board seats in different precision medicine and diagnostic organizations, including the European Personalised Medicine Association (EPEMED) and AdvaMedDx.

Werner Verbiest

Global Head, Janssen Diagnostics

As Global Head of the Disease Interception Accelerator (DIA), Ben Wiegand, Ph.D. is responsible for developing and implementing strategies for this autonomous incubator-like group that seeks to identify the root causes of disease and enable the development of interventions that stop the progression to disease. The DIA works to understand disease susceptibility, risk assessment and tackle the origins of disease, such as genetic predisposition, environmental exposure and phenotypic alterations.

Before joining Janssen Research & Development in 2014, Ben served as Vice President, Global Open Innovation and New Business Models Research & Development, Johnson & Johnson Group of Consumer Companies. He has a broad range of experience in delivering new innovation to the enterprise through the development of strategic partnerships, identifying and piloting new business and funding models, accelerating growth opportunities, and scouting and guiding emerging science to drive innovative growth. Ben also was the General Manager, Employer Franchise and Vice President, Science and Innovation, for Wellness & Prevention, Inc., a Johnson & Johnson company that helps organizations renew the health, energy and performance of their employees and members, and offers a portfolio of solutions to cover a broad spectrum of population health – from wellness and prevention, to behavioral health, to chronic disease support

Ben holds a B.S. degree in Chemistry from the University of Illinois, and both an M.A. and Ph.D. in Physical Chemistry from Harvard University, Massachusetts.

Benjamin C. Wiegand, Ph.D.

Global Head, Disease Interception Accelerator